Merck Tbk. vs Trimegah Bangun Persada Tbk. — how do they compare? Merck Tbk. trades at Rp3,840 (market cap 1.7T, 37.6K 24h volume), while Trimegah Bangun Persada Tbk. trades at Rp840 (market cap 52.69T, 53.38M 24h volume). The key difference: Trimegah Bangun Persada Tbk. is far larger — about 31× Merck Tbk.'s market cap, and Trimegah Bangun Persada Tbk. is more actively traded (53.38M versus 37.6K). Which is the better fit depends on your goals.
| MERK | NCKL | |
|---|---|---|
Market Cap | 1.7T | 52.69T |
Volume | 37.6K | 53.38M |
Lot | 376 | 533.77K |
Turnover | 144.47M | 45.04B |
Average Price | 3,842.23 | 843.75 |
Value | 144.47M | 45.04B |
Indicative Equilibrium Price | 3,840 | 840 |
Indicative Equilibrium Volume | 7 | 63.41K |
Trailing returns across standard periods
Latest headlines on both assets
PT Merck Tbk (the Company) is domiciled in Indonesia and located at Jl. TB Simatupang No. 8, Pasar Rebo, East Jakarta, was established in framework of Law No. 1 of 1967 and Law No. 11 of 1970 on foreign capital investment by deed of notary public Eliza Pondaag, SH dated 14 October 1970 No. 29. PT Merck Indonesia is a member of the Merck International Group. The company produces pharmaceutical products with production facility in East Jakarta. It commenced its operation in 1974 in manufacturing medical products, such as Songobian and Neurobion.
Read more on MERK →PT Trimegah Bangun Persada Tbk. (the Company) was established in Indonesia based on Notarial Deed of Erna Priyono, S.H., No. 03 dated September 6, 2004.
Read more on NCKL →